Our leadership, science and technologies have generated substantial funding through world-class investors
Industry Leaders in Healthcare Investment
ClavystBio’s mission is to accelerate the commercialization of life sciences breakthroughs into health impact. They invest and partner with innovators, entrepreneurs and founders to launch and grow global companies in Singapore. They foster partnerships among academics, industry and investors, and convene life sciences communities at our collaborative innovation space Node 1. Together, we advance Singapore as a global life sciences translational hub.
ClavystBio was conceived and launched by Temasek to be a venture builder, trusted partner, and keystone to catalyze global health solutions from Singapore. Since their inception in 2022, ClavystBio has committed over US$220m to biotech, diagnostics and digital health companies, as well as early-stage VC funds.
About Polaris Partners
Exceptional entrepreneurs. Remarkable bonds. Extraordinary companies. Since 1996, Polaris Partners has been guided by the fundamental beliefs that people come first and true partnerships make all the difference. Rooted in mutual respect and a shared passion for innovation, the company’s relationships with outstanding visionaries principally in technology and healthcare have helped to change the world for the better.
About Section 32
Section 32 (S32) is a venture capital firm investing at the frontiers of technology, healthcare and the life sciences with focus areas including biotechnology, therapeutics, advanced diagnostics, precision medicine, software, cybersecurity, machine learning and artificial intelligence. The firm’s goal is to improve the human condition by accelerating the discovery, development, adoption and distribution of important technologies and lifesaving medicines.